Menu

Study demonstrating high performance of Idylla™ liquid biopsy RAS tests to be presented at ASCO Annual Meeting

Non-regulated information

Results of the annual shareholders’ meeting held on 12 May 2017

Regulated information

Biocartis announces its new CEO

Inside information
Regulated information

Biocartis Q1 2017 Business Update

Regulated information

Disclosure of a transparency notification

(Article 14, paragraph 1 of the Belgian Act of 2 May 2007 on disclosure of major shareholdings)

Regulated information

Invitation to annual shareholders meeting

Regulated information

Biocartis establishes US subsidiary and appoints US General Manager

Non-regulated information

Biocartis announces publication of 2016 Annual Report

Regulated information

Biocartis receives grant for development of a fully automated MSI test

Test could be validated as prognostic test for colorectal cancer and predictive test for cancer immunotherapies
Non-regulated information

Study using Biocartis’ liquid biopsy BRAF assay shows new option for retreatment of melanoma patients

Study and editorial ‘A second chance for success with BRAF and MEK inhibitors in Melanoma’ published in renowned clinical journal The Lancet Oncology
Non-regulated information